Compare BioNano Genomics Inc (BNGO) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Gemini Space Station Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Gemini Space Station Inc trades at $4.13 (market cap $512.05M). The key difference: Gemini Space Station Inc is far larger — about 37.5× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.
| BNGO | GEMI | |
|---|---|---|
Market Cap | $13.66M | $512.05M |
Sector | Health | Technology |
52-Week High | $4.92 | $32.52 |
52-Week Low | $1.06 | $3.90 |
Enterprise Value | $16.26M | $502.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Gemini Space Station (GEMI) trades at $4.085, down 0.61% on the day, with technical indicators showing a bearish trend. The company reported significant losses with a net income margin of -278.9% in 2025 and has missed earnings expectations for three consecutive quarters. Recent developments include a $100 million investment from Winklevoss Capital and the launch of commission-free stock trading as part of its super app strategy.
Despite analyst consensus pointing to upside potential with a $6.33 price target, GEMI faces substantial execution risks amid ongoing securities lawsuits and persistent negative profitability. The stock presents high-risk speculative appeal for investors betting on the company's financial infrastructure transformation, but current fundamentals remain deeply concerning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
